Cancer vaccine

Worldwide Cancer Vaccines Industry to 2026 - Featuring AstraZeneca, GlaxoSmithKline and Moderna Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 2, 2021

Furthermore, numerous studies are being conducted in the field of viral recombinant cancer vaccines, which may reap positive results in future, primarily related to cancer vaccination.

Key Points: 
  • Furthermore, numerous studies are being conducted in the field of viral recombinant cancer vaccines, which may reap positive results in future, primarily related to cancer vaccination.
  • The National Cancer Institute (NCI) stated that the national spending on cancer care is expected to reach USD 156 billion by 2020.
  • Providence Therapeutics is a Toronto based clinical stage biotechnology company that develops cancer vaccines for human use.
  • Currently company is developing a personalized mRNA cancer vaccine designed to generate strong T cell responses that aim to kill cancer cells and destroy tumors in ovarian cancer, breast cancer and brain cancer.

DGAP-News: DEFENCE THERAPEUTICS ACCUVAC-D001 CANCER VACCINE GENERATES EFFECTIVE LONG-LASTING ANTI-TUMORAL RESPONSE

Retrieved on: 
Tuesday, May 25, 2021

Vancouver, BC, Canada, May 25, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is pleased to announce the completion of its AccuVAC-D001 cancer vaccine pre-clinical study.

Key Points: 
  • Vancouver, BC, Canada, May 25, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is pleased to announce the completion of its AccuVAC-D001 cancer vaccine pre-clinical study.
  • The AccuVAC-D001 cancer vaccine demonstrated a 70% cure rate of mice with pre-established solid tumors, this AccuVAC-D001 cancer vaccine confirms an effective anti-tumoral response.
  • Non-specific degradation of endocytosed cancer antigens by endo-lysosomal organelles in dendritic cells (DCs) is a major limitation in the field of cancer vaccination.
  • This puts Defence and its technology on the path for future development of universal therapeutic vaccines for cancer and infectious diseases vaccines", says Mr. Plouffe, CEO of Defence Therapeutics.

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform

Retrieved on: 
Thursday, May 13, 2021

b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.

Key Points: 
  • b'PROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT") announces the publication "Multistep screening of neoantigens\' HLA and TCRinterfaces improves prediction of survival" in Scientific Reports.
  • This study demonstrates a superior method of survival analysis for cancer patients using EVT\'s Ancer platform.
  • EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools to clinical research.\nEpiVax Therapeutics researchers develop improved method for cancer survival prediction.\nBuilt on validated in silico tools EpiMatrix and JanusMatrix , Ancer analyzesindividual cancer mutanomes to definethe presence of T cell epitopes likely to be immunogenic.
  • EVT\'s pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/improving-cancer-survival-predic...\n'

BostonGene Announces Cancer Research Collaboration with the Abramson Cancer Center of the University of Pennsylvania

Retrieved on: 
Tuesday, May 11, 2021

b"BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a Master Clinical Research Collaboration Agreement with the Abramson Cancer Center (ACC) of the University of Pennsylvania to support multiple research projects at the cancer center.\nThe first research project to arise from this collaboration aims to support clinical research focusing on personalized cancer vaccines, a new approach of active immunotherapy which utilizes the patient\xe2\x80\x99s own immune system to identify tumor specific neoantigens.

Key Points: 
  • b"BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a Master Clinical Research Collaboration Agreement with the Abramson Cancer Center (ACC) of the University of Pennsylvania to support multiple research projects at the cancer center.\nThe first research project to arise from this collaboration aims to support clinical research focusing on personalized cancer vaccines, a new approach of active immunotherapy which utilizes the patient\xe2\x80\x99s own immune system to identify tumor specific neoantigens.
  • BostonGene\xe2\x80\x99s advanced computational algorithms will identify cancer specific neoantigens and profile the immune activation status of the tumor by performing advanced multi-omics analysis, including the interpretation and visualization of cancer patient's genomic, transcriptomic and imaging datasets.
  • \xe2\x80\x9cWe are pleased to support the Abramson Cancer Center by providing sophisticated analytics and integration of scientific and clinical knowledge in an effort to improve the standard of care and redefine the treatment selection approach for cancer patients.\xe2\x80\x9d\nThe ACC, a global leader in basic, translational, clinical, and biomedical research for the advancement of cancer care, is a matrix cancer center embedded within the University of Pennsylvania and the University of Pennsylvania Health System.
  • BostonGene\xe2\x80\x99s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies.

Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings

Retrieved on: 
Monday, May 10, 2021

The full poster presentation from the ASCO Annual Meeting will be available on the Ultimovacs website on 4 June 2021.\nDetails of the investor events:\nPresenter: Carlos de Sousa, CEO.

Key Points: 
  • The full poster presentation from the ASCO Annual Meeting will be available on the Ultimovacs website on 4 June 2021.\nDetails of the investor events:\nPresenter: Carlos de Sousa, CEO.
  • Ultimovacs\xe2\x80\x99 lead universal cancer vaccine candidate UV1 leverages the high prevalence of the human telomerase (hTERT) to be effective across the dynamic stages of the tumor\xe2\x80\x99s growth and its microenvironment.
  • By directing the immune system to hTERT antigens that are present in over 80% of all cancers, UV1 drives CD4 helper T cells to the tumor with the goal of activating an immune system cascade to increase anti-tumor responses.
  • Ultimovacs\xe2\x80\x99 strategy is to clinically demonstrate UV1\xe2\x80\x99s impact in many cancer types and in combination with other immunotherapies.

Global Peptide Cancer Vaccine Market & Clinical Trials Insight to 2026 - Featuring Antigen Express, BioLife Science and Galena Biopharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021

Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management.

Key Points: 
  • Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management.
  • GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT).
  • Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells.
  • The vaccine is currently under clinical trials and applications to gain approval in other countries.\nApart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response.

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

Retrieved on: 
Tuesday, May 4, 2021

b'LEIDEN, Netherlands, May 4, 2021 /PRNewswire/ --ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company dedicated to developing immunotherapeutics for oncology and infectious diseases,announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines.

Key Points: 
  • b'LEIDEN, Netherlands, May 4, 2021 /PRNewswire/ --ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company dedicated to developing immunotherapeutics for oncology and infectious diseases,announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines.
  • This is the link to the online article: https://www.nature.com/articles/s41568-021-00346-0 .\nThe Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine trials.
  • Kees Melief, Chief Scientific Officer at ISA Pharmaceuticals, said: "Therapeutic cancer vaccines have undergone a resurgence in the past years.
  • It shows that targeted activation of the immune system by therapeutic vaccines can play an important role in beating cancer.

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

Retrieved on: 
Tuesday, May 4, 2021

b'LEIDEN, Netherlands, May 4, 2021 /PRNewswire/ --ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company dedicated to developing immunotherapeutics for oncology and infectious diseases,announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines.

Key Points: 
  • b'LEIDEN, Netherlands, May 4, 2021 /PRNewswire/ --ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company dedicated to developing immunotherapeutics for oncology and infectious diseases,announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines.
  • This is the link to the online article: https://www.nature.com/articles/s41568-021-00346-0 .\nThe Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine trials.
  • Kees Melief, Chief Scientific Officer at ISA Pharmaceuticals, said: "Therapeutic cancer vaccines have undergone a resurgence in the past years.
  • It shows that targeted activation of the immune system by therapeutic vaccines can play an important role in beating cancer.

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic

Retrieved on: 
Thursday, April 29, 2021

CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.

Key Points: 
  • CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.
  • "\nIn another action that further builds their IP portfolio, BioVaxys broadened the patent coverage for its bihaptenized tumor antigen vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") with additional claims for cervical cancer.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic

Retrieved on: 
Thursday, April 29, 2021

CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.

Key Points: 
  • CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.
  • "\nIn another action that further builds their IP portfolio, BioVaxys broadened the patent coverage for its bihaptenized tumor antigen vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") with additional claims for cervical cancer.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.